Table 4.
Study 2. Comparison between two groups of infants (≤2y/o) diagnosed of RSV infection
| Group 2 Delayed RSV diagnosis at the laboratory (n = 47) |
Group 3 RSV diagnosis at POCT (n = 160) |
P-value | % of infants with RSV diagnosis | |
|---|---|---|---|---|
| Clinical Symptoms | ||||
| Gestational age under 37 weeks | 26% (n = 12) | 14% (n = 22) | NS | 16.43 |
| Age under 6 months | 72% (n = 34) | 85% (n = 136) | <0.05 | 82.13 |
| Temperature above 38 °C | 36% (n = 17) | 42% (n = 67) | NS | 40.60 |
| Signs of Respiratory Distress | 68% (n = 32) | 89% (n = 143) | <0.001 | 84.54 |
| Feeding Difficulties | 32% (n = 15) | 33% (n = 52) | NS | 32.37 |
| Final diagnosis | ||||
| Bronchiolitis | 64% (n = 30) | 91% (n = 145) | <0.001 | 84.54 |
| Pneumopathy | 6% (n = 3) | 9% (n = 15) | NS | 8.71 |
| Asthma | 9% (n = 4) | 3% (n = 5) | NS | 4.35 |
| Patients Management | ||||
| Corticosteroids | 60% (n = 28) | 72% (n = 115) | NS | 69.08 |
| Antibiotics | 23% (n = 11) | 20% (n = 32) | NS | 20.77 |
| Aerosol Therapy | 72% (n = 34) | 86% (n = 138) | <0.05 | 83.10 |
| Epinephrine Aerosol | 53% (n = 25) | 71% (n = 113) | <0.05 | |
Infants with RSV diagnosis were compared at the laboratory (Group 2: SOFIA®RSV negative and PCR RSV positive) and at point-of-care testing (POCT, Group 3: SOFIA®RSV positive)
Aerosol Therapy included Epinephrine, Salbutamol, Ipratropium bromide, Budesonide or normal saline
NS Non Significant. Chi2 test was used for statistical comparison